Immunis Welcomes Dr Peter Diamandis To The Executive Advisory Board

Bonisiwe Shabane

-Dec 28, 2025, 4:54 AM

immunis welcomes dr peter diamandis to the executive advisory board

Dr. Peter Diamandis, Immunis Inc Executive Advisory Board Member Named by Fortune as one of the “World’s 50 Greatest Leaders,” Dr. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which funds the design and operation of large-scale incentive competitions. As the executive founder of Singularity University, Dr. Diamandis counsels the world’s leaders on exponentially growing technologies with programs such as Abundance360 and the Abundance Platinum Longevity Program.

He is the co-Founder and Vice-Chairman of the cellular therapeutics company, Celularity, Inc., and of Vaxxinity, Inc., which develops vaccines against COVID and chronic disease. Dr. Diamandis is also the co-Founder & Executive Chairman of Fountain Life, a co-Founder of BOLD Capital Partners and a Board Member of four successful SPAC exits. Dr. Diamandis’ books, blogs, podcasts and webinars educate millions of individuals regularly. Immunis is honored to have such an innovative expert join the team.

“I haven’t been this excited about a biotech company in a long time! The approach Immunis is taking to reproduce the stem cell secretome and the focus on Sarcopenia is brilliant. Besides the multitude of potential longevity related benefits, battling Sarcopenia could have one of the biggest impacts on healthy aging we’ve seen this decade,” says Dr. Peter H. Diamandis. Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline.

The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technology to deliver all natural, all human immune modulators in their natural, relative physiological concentrations. IRVINE, Calif. , Sept. 20, 2022 /PRNewswire/ -- Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a testing, welcomes Peter H. Diamandis, M.D. to the Executive Advisory Board.

Dr. Diamandis received degrees in molecular genetics and aerospace engineering from MIT and is a Harvard-trained physician. His entrepreneurship has led to the creation of over 25 companies in the areas of space, education, venture capital and longevity. Named by Fortune as one of the "World's 50 Greatest Leaders," Dr. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which funds the design and operation of large-scale incentive competitions. As the executive founder of Singularity University, Dr.

Diamandis counsels the world's leaders on exponentially growing technologies with programs such as Abundance360 and the Abundance Platinum Longevity Program. He is the co-Founder and Vice-Chairman of the cellular therapeutics company, Celularity, Inc., and of Vaxxinity, Inc., which develops vaccines against COVID and chronic disease. Dr. Diamandis is also the co-Founder & Executive Chairman of Fountain Life, a co-Founder of BOLD Capital Partners and a Board Member of four successful SPAC exits. Dr. Diamandis' books, blogs, podcasts and webinars educate millions of individuals regularly.

Immunis is honored to have such an innovative expert join the team. "I haven't been this excited about a biotech company in a long time! The approach Immunis is taking to reproduce the stem cell secretome and the focus on Sarcopenia is brilliant. Besides the multitude of potential longevity related benefits, battling Sarcopenia could have one of the biggest impacts on healthy aging we've seen this decade," says Dr. Peter H. Diamandis.

"I haven't been this excited about a biotech company in a long time!" - Dr. Peter H. Diamandis. About Immunis Inc.Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis' leading-edge capabilities in stem cell technology to deliver all natural, all human immune modulators in their natural, relative physiological concentrations. Peter Diamandis, M.D.

received degrees in molecular genetics and aerospace engineering from MIT and is a Harvard-trained physician. His entrepreneurship has led to the creation of over 25 companies in the areas of space, education, venture capital and longevity. Named by Fortune as one of the “World’s 50 Greatest Leaders,” Dr. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which funds the design and operation of large-scale incentive competitions. As the executive founder of Singularity University, Dr. Diamandis counsels the world’s leaders on exponentially growing technologies with programs such as Abundance360 and the Abundance Platinum Longevity Program.

He is the co-Founder and Vice-Chairman of the cellular therapeutics company, Celularity, Inc., and of Vaxxinity, Inc., which develops vaccines against COVID and chronic disease. Dr. Diamandis is also the co-Founder & Executive Chairman of Fountain Life, a co-Founder of BOLD Capital Partners and a Board Member of four successful SPAC exits. Dr. Diamandis’ books, blogs, podcasts and webinars educate millions of individuals regularly. Immunis Named by The Healthcare Technology Report as one of the “Top 50 Healthcare Technology Companies of 2025”

Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, today announced it has been named one of the Top 50 Healthcare Technology Companies of 2025 by The... The recognition follows the company’s recent publication in Obesity showing body fat loss and increased lean muscle mass, a first-in-class phase 2 trial of its treatment candidate for sarcopenic obesity, and Series A financing. Immunis Publishes Research Showing Body Fat Loss and Reversal of Liver Steatosis and Fibrosis, While Increasing Lean Muscle Mass Immunis, Inc., a clinical-stage biotech developing innovative stem cell-derived biologics for age and disease-related immune dysregulation, announces the publication of its peer-reviewed research in collaboration with Dr. Micah Drummond from the University of Utah. The study published in Obesity is titled, “Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice.”

Immunis Honored with the National Academy of Medicine’s 2025 Healthy Longevity Catalyst Award Peter H. Diamandis (/ˌdiːəˈmændɪs/ DEE-ə-MAN-diss; born May 20, 1961) is an American engineer, physician,[1] and entrepreneur. He is best known as the founder and chairman of the XPRIZE Foundation, and the cofounder and executive chairman of Singularity University. He is also cofounder and former CEO of the Zero Gravity Corporation, cofounder and vice chairman of Space Adventures Ltd., founder and chairman of the Rocket Racing League, cofounder of the International Space University,... Diamandis was born in the Bronx, New York, to Greek immigrants.[3] At age 12, Diamandis won first place a rocket design competition.[4]

After graduating from Great Neck North High School in 1979, Diamandis attended Hamilton College for his first year, then transferred to the Massachusetts Institute of Technology to study biology and physics. During his second year at MIT in 1980, he cofounded Students for the Exploration and Development of Space.[5] Diamandis graduated from MIT in 1983[6][7] and entered Harvard Medical School to pursue his MD through the Harvard–MIT Program in Health Sciences and Technology. During his second year of medical school, he cofounded the Space Generation Foundation to promote projects and programs that would help the "Space Generation"—all those born since the flight of Sputnik—get off the planet.[4] In 1986, Diamandis put his medical degree on hold and returned to MIT to pursue a master's degree in aeronautics and astronautics, conducting research at NASA Johnson Space Center, the MIT Man Vehicle Laboratory... at MIT, Diamandis returned to Harvard to complete his M.D.[9]

“The Time is Now” to Maximize Human Healthspan: A Discussion with Peter Diamandis, Hans Keirstead, Daniel Kraft and Jane Metcalfe Immunis presents a one-of-a-kind film with world-renowned longevity innovators who examine the future of aging. Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing human healthspan.

(Graphic: Business Wire) IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film (The Time is Now) with world-renowned longevity innovators who examine the future... Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing human health.

With over 50,000 biotech companies dedicated to longevity, the opportunity to increase our healthspan is more attainable than ever before. “It’s this decade that we have the tools, both from a data and computational standpoint, [and] also from a biology standpoint,” says Dr. Diamandis. Dr. Diamandis is an esteemed leader in space exploration and innovation, who created the XPRIZE Foundation to drive revolutionary technology development and co-founded Singularity to guide future-focused education. His work with Fountain Life further showcases his commitment to extending healthy years through data-driven modeling and AI.

The world is evolving in such a way that people have more access to personalized resources for their health journey. It’s no longer a question of whether we want to live longer, but rather, how can we use our current resources to help us achieve that goal. “Lifespan is one thing, but it is more important that we live well,” says Dr. Hans Keirstead, Chairman of Immunis. People don’t just want to live to 100, they want to thrive in their later years. Lucky for us, in this era, we have the tools.

Immunis Welcomes Dr Peter Diamandis To The Executive Advisory Board

People Also Search

Dr. Peter Diamandis, Immunis Inc Executive Advisory Board Member Named

He Is The Co-Founder And Vice-Chairman Of The Cellular Therapeutics

“I Haven’t Been This Excited About A Biotech Company In

The STEM Product Line Leverages Immunis’ Leading-edge Capabilities In Stem

Dr. Diamandis Received Degrees In Molecular Genetics And Aerospace Engineering